Pulmonary Embolism Drugs Market size was over USD 1.72 Billion in 2023 and is set to cross USD 3.63 Billion by the end of 2036, witnessing more than 6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of pulmonary embolism drugs is estimated at USD 1.74 Billion. The growth of the market can be attributed to the increasing prevalence of cardiovascular diseases owing to the malfunction of arteries. Cardiovascular diseases are associated with blood vessels or the heart. It is a medical condition in which the circulation of blood to the brain, heart, and body is reduced owing to blood clots. Based on the data provided by the World Health Organization (WHO), in 2019, around 17.9 million people were observed to be suffering from cardiovascular disease.
In addition to these, global market trends such as, rising awareness of healthy lifestyles promoting the importance of early diagnosis and a surge in the cases of cancer are estimated to expand the market size over the forecast period. Pulmonary embolism is observed to cause a significant number of cancers in the global population. For instance, around 5% of cancer-related deaths are accounted by pulmonary emboli which is a type of blood clot in the lungs. Furthermore, people suffering from cancer associated with the brain, lungs, stomach, and people who are noticed to be undergoing chemotherapy are at higher risk of getting pulmonary embolism. For instance, it was projected that there is estimated to be around 22 million cancer survivors owing to chemotherapy by the year 2032. Hence, all these factors are anticipated to influence the market growth positively over the forecast period.
Growth Drivers
Growing Prevalence of Bone Fractures - Bone fracture is one of the major reasons to cause of pulmonary embolism since during bone injury, fat around the muscle turns into broken blood vessels. When these symptoms are developed owing to a lack of medical attention, they turn into embolism syndrome. For instance, it was anticipated that nearly 1 million individuals suffer from bone fractures annually.
Rising Awareness of Pulmonary Embolism Across the Globe - In modern times, owing to the developing medical technology and the launch of new innovative diagnostic devices has spurred awareness of the early diagnosis of pulmonary embolism which is anticipated to hike the market growth over the forecast period. It was estimated that around 35% of people lose their lives before getting any sort of diagnosis and treatment.
Increasing Prevalence of Pulmonary Embolism (PE) - The prevalence of pulmonary embolism is so high that it is third behind heart attack and stroke. For instance, approximately 300,000 people lose their lives every year in the United States.
Growing Incidences of Heart Failure to Boost Market Growth - Heart failure is also considered to be one of the major causes of pulmonary embolism. For instance, it was estimated that approximately 6 million Americans aged above 20 have heart failure while 900,000 new cases of heart failure are diagnosed every year in the American region.
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
6% |
|
Base Year Market Size (2023) |
USD 1.72 Billion |
|
Forecast Year Market Size (2036) |
USD 3.63 Billion |
|
Regional Scope |
|
Drug Class (Thrombolytics, Thrombosis, Heparins, Thrombin Inhibitors)
The global pulmonary embolism drugs market is segmented and analyzed for demand and supply by drug class into thrombolytics, thrombosis, heparins, thrombin inhibitors, and others. Out of these types of drug classes, the thrombosis segment is estimated to gain the largest market share in the year 2036. Thrombosis is a medical condition that is mainly caused by a lump of thick blood clots that forms in a blood vessel in the heart. Venous thrombosis is observed to be quite prevalent across the globe which is estimated to hike the market growth over the forecast period. For instance, it was expected that every year, in every 1000, 1 of them suffer from venous thrombosis. The occurrence rate of thrombosis rises after the age of 45 and is quite higher in men than women. The risk factors of thrombosis include immobility, hospitalization, trauma, pregnancy, and others.
Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy)
The global pulmonary embolism drugs market is also segmented and analyzed for demand and supply by distribution channel into hospital pharmacy, drug store, online pharmacy, and others. Amongst these segments, the hospital pharmacies segment is expected to garner a significant share in the year 2036. Hospitals are noticed to have luxury medical services in a single place. A huge staff of medical professionals is available to provide healthcare services 24/7. Furthermore, every nation is observed to spend a significant amount of money to develop hospital infrastructures to provide better medical services. The growth in the number of hospitals across the globe is anticipated to be backed by increasing income, population demographics, growing health awareness, and others. For instance, in India, the number of private hospitals was estimated to be around 40,000 while the number of public hospitals was anticipated to be nearly 25,000 in 2019.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Distribution Channel |
|
North American Market Forecast
The North American pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the rising healthcare expenditure backed by the escalating government spending to develop healthcare services. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America is valued at USD 10,050.279. Moreover, the presence of major pharmaceutical companies in the region is estimated to boost market growth during the forecast period.
APAC Market Statistics
The Asia Pacific pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed majorly to the high prevalence of cancer in the region backed by the growing government initiatives to launch and support programs to provide medical services for people living with cancer. For instance, in 2020, approximately 150 thousand people were estimated to be living with cancer in the Asia Pacific along with the high geriatric population, both of which are major causes of pulmonary embolism.
Europe Market Forecast
The Europe pulmonary embolism drugs market, amongst the market in all the other regions, is projected to hold a notable share during the forecast period. Factors such as, a higher prevalence of cancer in the region and higher demand for healthcare solution backed by the increasing geriatric population is estimated to propel the growth of the market over the forecast period. Moreover, the surge in research & development of pulmonary embolism drugs in the region is also anticipated to drive market growth over the forecast period.
Janssen Pharmaceuticals, Inc. revealed the results from Phase 3 A DUE study. This Phase 3 study is to represent investigational single-tablet combination therapy.
Novartis AG got approval for Tafinlar (dabrafenib) + Mekinist (trametinib) from U.S. Food and Drug Administration (FDA). These medications are used to treat pediatric patients or people with brain cancer.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?